COLTENE (CLTN) H2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2025 earnings summary
13 Mar, 2026Executive summary
Net sales in 2025 were CHF 240 million, flat in local currencies but down 4.0% in Swiss francs due to FX headwinds, with no significant market share changes.
Second half of 2025 saw a 4.7% growth in local currencies and an 11% operating margin, reflecting successful strategic execution.
EBIT margin dropped to 8.8% from 10.7% year-over-year; net profit decreased 27% to CHF 14.9 million.
Free cash flow fell to CHF 8.1 million, mainly due to lower net profit and increased working capital.
Strategic investments in product innovation, digital marketing, and a new AI-capable CRM system supported operational improvements.
Financial highlights
Net sales reached CHF 240 million, a 0.2% decrease in local currencies and a 4.0% decrease in Swiss francs.
EBIT was CHF 21 million, with a margin of 8.8%, down 1.9 percentage points year-over-year.
Net profit fell 27% to CHF 14.9 million, with a profit margin of 6.2%.
Free cash flow was CHF 8.1 million, down 59.5% year-over-year.
Equity ratio decreased to 54.9% from 58.2%.
Outlook and guidance
Targeting low single-digit sales growth for 2026, aiming to outperform the market despite ongoing volatility.
EBIT margin guidance for 2026 is 9%-10%, with a long-term target of 13–15% by 2028, delayed by one year.
Profitability improvement expected from volume growth, operational efficiencies, price increases, and reduced tariff impact.
Medium-term targets include annual sales growth of 3–5% in local currencies and a payout ratio of about 70%.
Latest events from COLTENE
- Net sales down 4.4%, EBIT margin at 5.1%, free cash flow up, outlook for modest growth.CLTN
H1 202631 Jul 2026 - Net profit rose 3.9% despite lower sales, with strong margins and a positive outlook.CLTN
H1 202424 Jul 2026 - Net profit rose to CHF 20.5m as sales and margins improved, led by North America.CLTN
H2 202424 Jul 2026 - Sales and profit declined sharply in H1 2025, but a stronger second half is anticipated.CLTN
H1 202524 Jul 2026 - Aims for 3–5% annual growth, 13–15% EBIT margin by 2027, and leadership in dental innovation.CLTN
CMD 2024 Presentation20 Feb 2026